A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.

@article{Arcinue2013ACB,
  title={A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.},
  author={Cheryl A. Arcinue and O. Cer{\'o}n and C. S. Foster},
  journal={Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics},
  year={2013},
  volume={29 5},
  pages={
          501-7
        }
}
  • Cheryl A. Arcinue, O. Cerón, C. S. Foster
  • Published 2013
  • Medicine
  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • PURPOSE To evaluate the efficacy and safety of the fluocinolone acetonide (Retisert) implant compared with the dexamethasone (Ozurdex) implant in patients with noninfectious uveitis. DESIGN Comparative case series. STUDY PARTICIPANTS Twenty-seven eyes received either the fluocinolone acetonide (FA) (n=16) or dexamethasone (n=11) implant. METHODS Chart review of patients at the Massachusetts Eye Research and Surgery Institution (MERSI) was done and patients were selected and matched… CONTINUE READING
    Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis
    • 28
    • Highly Influenced

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 13 REFERENCES
    The dexamethasone drug delivery system: Indications and evidence
    • 120
    Uveitis: A Potentially Blinding Disease
    • 197
    OUTCOME OF FLUOCINOLONE ACETONIDE IMPLANT (RETISERT™) REIMPLANTATION FOR CHRONIC NONINFECTIOUS POSTERIOR UVEITIS
    • 45
    • Highly Influential